Novo: Amycretin Causes 22 Percent Weight Loss

Published on January 24, 2025

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks. Shares jumped on the release and traded up 7% at…

Read Full Article (External Site)